Amyotrophic lateral sclerosis: New genes, new models, and new mechanisms

F1000 Biology Reports

Volumn 3, Issue 1, 2011, Pages

  Vande Velde, Christine ^a,b   Dion, Patrick A ^a,b   Rouleau, Guy A ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; APOLIPOPROTEIN E; COPPER ZINC SUPEROXIDE DISMUTASE; GLYCINE; POLYGLUTAMINE; RNA BINDING PROTEIN; TAR DNA BINDING PROTEIN; VALOSIN CONTAINING PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; FRONTOTEMPORAL DEMENTIA; GENE; GENE EXPRESSION; GENE MUTATION; GROWTH; HUMAN; MODEL; MOLECULAR PATHOLOGY; MOTONEURON; NERVE DEGENERATION; NONHUMAN; OPEN ANGLE GLAUCOMA; PAGET BONE DISEASE; REVIEW; RNA METABOLISM; SPINAL MUSCULAR ATROPHY;

EID: 80053537470     PISSN: 17404118     EISSN: 1757594X     Source Type: Journal    
DOI: 10.3410/B3-18     Document Type: Review

References (56)

1. Dion PA, Daoud H, Rouleau GA: Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet 2009, 10:769-82.
2. Boillee S, Vande Velde C, Cleveland DW: ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:1-21.
3. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V: Doseranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996, 347:1425-31. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
4. Bensimon G, Lacomblez L, Meininger V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994, 330:585-91. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
5. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
6. Ilieva H, Polymenidou M, Cleveland DW: Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009, 187:761-72. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
7. Lagier-Tourenne C and Cleveland DW: Rethinking ALS: the FUS about TDP-43. Cell 2009, 136:1001-4. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
8. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H: Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465:223-6. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
9. Millecamps S, Boillee S, Chabrol E, Camu W, Cazeneuve C, Salachas F, Pradat PF, Danel-Brunaud V, Vandenberghe N, Corcia P, Le FN, Lacomblez L, Bruneteau G, Seilhean D, Brice A, Feingold J, Meininger V, Leguern E: Screening of OPTN in French familial amyotrophic lateral sclerosis. Neurobiol Aging 2011, 32:557-3. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
10. Sugihara K, Maruyama H, Kamada M, Morino H, Kawakami H: Screening for OPTN mutations in amyotrophic lateral sclerosis in a mainly Caucasian population. Neurobiol Aging 2011, 32:1923.e9-10. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
11. Del BR, Tiloca C, Pensato V, Corrado L, Ratti A, Ticozzi N, Corti S, Castellotti B, Mazzini L, Soraru G, Cereda C, D'Alfonso S, Gellera C, Comi GP, Silani V: Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011, [Epub ahead of print]. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
12. Ticozzi N, Vance C, Leclerc AL, Keagle P, Glass JD, McKenna- Yasek D, Sapp PC, Silani V, Bosco DA, Shaw CE, Brown RH Jr., Landers JE: Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. Am J Med Genet B Neuropsychiatr Genet 2011, 156:285-90. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
13. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M: Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-65. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
14. Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y, Dewey CM, Roth FP, Herz J, Peng J, Moore MJ, Yu G: Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem 2011, 286:1204-15. F1000 Factor 8 Evaluated by Guy Rouleau 17 Aug 2011
15. Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J, Hortobagyi T, Nishimura AL, Zupunski V, Patani R, Chandran S, Rot G, Zupan B, Shaw CE, Ule J: Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci 2011, 14:452-8. F1000 Factor 8 Evaluated by Guy Rouleau 17 Aug 2011
16. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L, Bennett CF, Yeo GW, Cleveland DW: Long pre-mRNA depletion and RNAmissplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 2011, 14:459-68. F1000 Factor 9 Evaluated by Valina Dawson 04 May 2011, Guy Rouleau 17 Aug 2011
17. Xiao S, Sanelli T, Dib S, Sheps D, Findlater J, Bilbao J, Keith J, Zinman L, Rogaeva E, Robertson J: RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. Mol Cell Neurosci 2011, 47:167-80. F1000 Factor 8 Evaluated by Guy Rouleau 17 Aug 2011
18. McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, Rouleau GA, Vande Velde C: TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet 2011, 20:1400-10.
19. Freibaum BD, Chitta RK, High AA, Taylor JP: Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res 2010, 9:1104-20. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
20. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderwyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, Petrucelli L, Wolozin B: Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One 2010, 5:e13250. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
21. Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, Silani V, Ratti A: TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem 2009, 111:1051-61. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
22. Bosco DA, Lemay N, Ko HK, Zhou H, Burke C, Kwiatkowski TJ Jr., Sapp P, McKenna-Yasek D, Brown RH Jr., Hayward LJ: Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet 2010, 19:4160-75. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
23. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, Than ME, Mackenzie IR, Capell A, Schmid B, Neumann M, Haass C: ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J 2010, 29:2841-57. F1000 Factor 7 Evaluated by Yuh Min Chook 09 Nov 2010, Guy Rouleau 17 Aug 2011
24. Gal J, Zhang J, Kwinter DM, Zhai J, Jia H, Jia J, Zhu H: Nuclear localization sequence of FUS and induction of stress granules by ALS mutants. Neurobiol Aging 2010, [Epub ahead of print]. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
25. Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong MJ: Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res 2009, 1249:202-11. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
26. Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, van Es MA, Sapp PC, van Vught PW, McKenna-Yasek DM, Blauw HM, Cho TJ, Polak M, Shi L, Wills AM, Broom WJ, Ticozzi N, Silani V, Ozoguz A, Rodriguez-Leyva I, Veldink JH, Ivinson AJ, Saris CG, Hosler BA, Barnes-Nessa A, Couture N, Wokke JH, Kwiatkowski TJ Jr., Ophoff RA, Cronin S, Hardiman O, et al.: Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2009, 106:9004-9. F1000 Factor 11 Evaluated by Stanley Appel 09 Jun 2009, Guy Rouleau 17 Aug 2011
27. Traynor BJ, Nalls M, Lai SL, Gibbs RJ, Schymick JC, Arepalli S, Hernandez D, van der Brug MP, Johnson JO, Dillman A, Cookson M, Moglia C, Calvo A, Restagno G, Mora G, Chio A: Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a populationbased cohort of ALS patients. Proc Natl Acad Sci U S A 2010, 107:12335-8. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
28. Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, de CM, Meyer T, Tysnes OB, Auburger G, Gispert S, Bonini NM, Andersen PM, Gitler AD: Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet 2011, 20:1697-700. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
29. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay- Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rub U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitler AD: Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010, 466:1069-75. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
30. Yu Z, Zhu Y, Chen-Plotkin AS, Clay-Falcone D, McCluskey L, Elman L, Kalb RG, Trojanowski JQ, Lee VM, van Deerlin VM, Gitler AD, Bonini NM: PolyQ Repeat Expansions in ATXN2 Associated with ALS Are CAA Interrupted Repeats. PLoS One 2011, 6: e17951. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
31. Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, Dejesus-Hernandez M, Adamson J, Li M, Volkening K, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Woodruff BK, Knopman DS, White CL III, van Gerpen JA, Meschia JF, Mackenzie IR, Boylan K, Boeve BF, Miller BL, Strong MJ, Uitti RJ, Younkin SG, Graff- Radford NR, et al.: Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet 2011, 20:3207-12. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
32. Daoud H, Belzil V, Martins S, Sabbagh M, Provencher P, Lacomblez L, Meininger V, Camu W, Dupre N, Dion PA, Rouleau GA: Association of Long ATXN2 CAG Repeat Sizes With Increased Risk of Amyotrophic Lateral Sclerosis. Arch Neurol 2011, 68:739-42.
33. Cronin S, Blauw HM, Veldink JH, van Es MA, Ophoff RA, Bradley DG, van den Berg LH, Hardiman O: Analysis of genome-wide copy number variation in Irish and Dutch ALS populations. Hum Mol Genet 2008, 17:3392-8. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
34. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993, 90:1977-81. (Pubitemid 23069980)
35. Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, Jhaveri BS, Karlawish JH, Pestronk A, Smith TW, Tu PH, Watts GD, Markesbery WR, Smith CD, Kimonis VE: Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 2006, 65:571-81. (Pubitemid 44288941)
36. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE: Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004, 36:377-81. (Pubitemid 38437260)
37. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez DG, Arepalli S, Chong S, Schymick JC, Rothstein J, Landi F, Wang YD, Calvo A, Mora G, Sabatelli M, Monsurro MR, Battistini S, Salvi F, Spataro R, Sola P, Borghero G, et al.: Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010, 68:857-64. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
38. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM: Ubiquitinated TDP- 43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-33. F1000 Factor 11 Evaluated by Stanley Appel 13 Feb 2007, Guy Rouleau 17 Aug 2011
39. Neary D, Snowden JS, Mann DM: Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). J Neurol Sci 2000, 180:15-20.
40. Borroni B, Bonvicini C, Alberici A, Buratti E, Agosti C, Archetti S, Papetti A, Stuani C, Di LM, Gennarelli M, Padovani A: Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat 2009, 30:E974-83. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
41. Borroni B, Archetti S, Del BR, Papetti A, Buratti E, Bonvicini C, Agosti C, Cosseddu M, Turla M, Di LD, Pietro CG, Gennarelli M, Padovani A: TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. Rejuvenation Res 2010, 13:509-17. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
42. Liu J, Lillo C, Jonsson PA, Vande Velde C, Ward CM, Miller TM, Subramaniam JR, Rothstein JD, Marklund S, Andersen PM, Brannstrom T, Gredal O, Wong PC, Williams DS, Cleveland DW: Toxicity of Familial ALS-Linked SOD1 Mutants from Selective Recruitment to Spinal Mitochondria. Neuron 2004, 43:5-17. F1000 Factor 6 Evaluated by Albert La Spada 17 Nov 2004
43. Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, Trotti D, Brown RH, Jr.: Amyotrophic Lateral Sclerosis-Associated SOD1 Mutant Proteins Bind and Aggregate with Bcl-2 in Spinal Cord Mitochondria. Neuron 2004, 43:19-30. F1000 Factor 7 Evaluated by Albert La Spada 17 Nov 2004, Guy Rouleau 17 Aug 2011
44. Vande Velde C, Miller TM, Cashman NR, Cleveland DW: Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci U S A 2008, 105:4022-7. (Pubitemid 351723517)
45. Rakhit R, Robertson J, Vande Velde C, Horne P, Ruth DM, Griffin J, Cleveland DW, Cashman NR, Chakrabartty A: An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med 2007, 13:754-9. F1000 Factor 8 Evaluated by Nereo Bresolin 20 Jun 2007, Guy Rouleau 17 Aug 2011
46. Gros-Louis F, Soucy G, Lariviere R, Julien JP: Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010, 113:1188-99. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
47. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, Jacobsson J, Rosquist R, Marklund SL, Brannstrom T: Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 2010, 5:e11552. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
48. Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan- Barmatz V, Cleveland DW: Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron 2010, 67:575-87. F1000 Factor 6 Evaluated by Guy Rouleau 17 Aug 2011
49. Li Q, Vande Velde C, Israelson A, Xie J, Bailey AO, Dong MQ, Chun SJ, Roy T, Winer L, Yates JR, Capaldi RA, Cleveland DW, Miller TM: ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc Natl Acad Sci U S A 2010, 107:21146-51. F1000 Factor 6 Evaluated by Nereo Bresolin 15 Dec 2010
50. Vande Velde C, McDonald KK, Boukhedimi Y, McAlonis-Downes M, Lobsiger CS, Bel Hadj S, Zandona A, Julien JP, Shah SB, Cleveland DW: Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset. PLoS One 2011, 6:e22031.
51. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, Goolsby H, Fontaine BA, Lemay N, McKenna-Yasek D, Frosch MP, Agar JN, Julien JP, Brady ST, Brown RH, Jr.: Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010, 13:1396-403. F1000 Factor 9 Evaluated by Stanley Appel 19 Nov 2010, Guy Rouleau 17 Aug 2011
52. Banci L, Bertini I, Boca M, Girotto S, Martinelli M, Valentine JS, Vieru M: SOD1 and amyotrophic lateral sclerosis: mutations and oligomerization. PLoS One 2008, 3:e1677.
53. Ezzi SA, Urushitani M, Julien JP: Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem 2007, 102:170-8. (Pubitemid 46906269)
54. Heiman-Patterson TD, Sher RB, Blankenhorn EA, Alexander G, Deitch JS, Kunst CB, Maragakis N, Cox G: Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers. Amyotroph Lateral Scler 2011, 12:79-86.
55. The Jackson Laboratory: 'Manuals'. [http://jaxmice.jax.org/manual/ index.html#als]
56. Zinman L and Cudkowicz M: Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol 2011, 10:481-90.